Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefining the boundaries of LDL-C reduction and patient care in atherosclerotic disease.
Levothyroxine in the Ageing Patient: Re-evaluating Cardiovascular Outcomes in Subclinical Hypothyroidism through the ACEL-UK-ETT Trial

Levothyroxine in the Ageing Patient: Re-evaluating Cardiovascular Outcomes in Subclinical Hypothyroidism through the ACEL-UK-ETT Trial

This review analyzes the ACEL-UK-ETT emulated target trial, demonstrating that long-term levothyroxine therapy in older adults with subclinical hypothyroidism significantly reduces cardiovascular events and all-cause mortality without compromising bone health, provided age-specific TSH thresholds are utilized.
Impact of Polygenic Risk Scores on the Clinical Presentation and Glycaemic Variability of GCK-MODY

Impact of Polygenic Risk Scores on the Clinical Presentation and Glycaemic Variability of GCK-MODY

This article explores how polygenic background modifies GCK-MODY clinical phenotypes, influencing HbA1c levels and diagnostic thresholds. Findings highlight the distinct polygenic patterns in GCK-MODY compared to HNF1A-MODY, emphasizing the interaction between monogenic and polygenic factors in diabetes.